Clinical Trials Successful

Auckland, New Zealand - Intradermal injection of a purified cell wall component from heat-killed Mycobacterium vaccae may one day be used to treat children with severe atopic dermatitis, if a clinical program carried out by a New Zealand company continues to be successful.

Related Videos
Related Content

Discovering Dermatology Times: May 2023

May 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Dermatologic Concerns Among Veterans and Members of the Military

May 29th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

The Weekly Roundup: May 22-26

May 26th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023

Discovering Dermatology Times: May 2023

May 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Dermatologic Concerns Among Veterans and Members of the Military

May 29th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

The Weekly Roundup: May 22-26

May 26th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023

Discovering Dermatology Times: May 2023

May 29th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Dermatologic Concerns Among Veterans and Members of the Military

May 29th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

The Weekly Roundup: May 22-26

May 26th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023
© 2023 MJH Life Sciences

All rights reserved.